Eptinezumab not checked
H. Lundbeck A/S · Lu AG09221
FollowEvery change as it happens, and a Monday email
Trials
4 active
17 in total · 6 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Eptinezumab will be administered per dose and schedule specified in the arm.”In the company’s words, NCT04965675 on ClinicalTrials.gov
- Tested for
- Chronic Migraine in Children, Episodic Migraine, Migraine
- Main trialPhase 3
- “To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.”In the company’s words, NCT04965675 on ClinicalTrials.gov
- Other names
- Vyepti · Lu AG09221
Other drugs for Episodic Migraine
- ElismetrepTriGemX Bio, Inc. · Tanabe Pharma Corporation · Phase 3
- UbrogepantAbbVie · Phase 3
- BR005-036CBrise Pharmaceuticals Co., Ltd. · Phase 3
- AtogepantAbbVie · Phase 3
- ErenumabAmgen · Phase 3
- MEDI0618AbbVie · Phase 2
Coming up3
- 26 Mar 2027Phase 3 trial completes · ClinicalTrials.gov
- 6 Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Apr 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials17
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 26 Mar 2027 | A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | |
| Phase 3Recruiting | 6 Jul 2027 | A Study of Eptinezumab in Pediatric Participants With Episodic Migraine | |
| Phase 3Recruiting | 30 Apr 2028 | A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine | |
| Phase 4Terminated | 17 Feb 2023 | Real World Effectiveness of Eptinezumab in Participants With Migraine | |
| Phase 4Completed | 22 Oct 2024 | A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache | |
| Phase 4Completed | 2 Sep 2026 | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | |
| Phase 3Completed | 8 Jul 2020 | A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine | |
| Phase 3Completed | 15 Jul 2021 | A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments | |
| Phase 3Completed | 23 May 2022 | Eptinezumab in Adults With Migraine and Medication Overuse Headache | |
| Phase 3Completed | 14 Jun 2023 | Eptinezumab in Participants With Episodic Cluster Headache | |
| Phase 3Completed | 29 Jun 2023 | A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH) | |
| Phase 3Completed | 8 Jun 2024 | Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan | |
| Phase 3Completed | 1 Oct 2024 | Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine | |
| Phase 1Completed | 20 Jul 2021 | Safety, Tolerability and Pharmacokinetics of Eptinezumab in Healthy Chinese Subjects | |
| Phase 1Completed | 20 Oct 2022 | A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab | |
| Phase 2Ended | not given | CAT-Trial: CGRP monoclonal Antibody for Treatment of painful diabetic neuropathy: a double-blind, multicenter, placebo-controlled, international phase II clinical trial | |
| Phase 4Authorised | not given | Exploring Eptinezumab: Unveiling Peripheral and Central Mechanisms of Action and Searching for Biomarkers of Patient Response (EUPHORIA Study) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026